Institute for Clinical Research Official Portal

Clinical Research Centre

Hospital Ampang
Selangor

WhoWe Are

Clinical Research Centre Hospital Ampang (CRC HAMP) is currently headed by Dr. Jerome Tan Tsen Chuen, Consultant Haematologist, since 2019. CRC HAMP continues to grow. CRC consists of 2 staffs of Hospital Ampang, 4 ICR staffs and 7 Clinical Research Malaysia (CRM) staffs. CRC HAMP is located at Level 3 Specialist Office. CRC HAMP is one of the 37 CRC networks under the Institute of Clinical Research (ICR), Malaysia. CRC HAMP was initiated in Year 2007, has grown to become an efficient and accountable centre to conduct quality and ethical research in order to enhance patient outcome. It was established to provide assistance in clinical studies, especially in the promotion of research among Hospital Ampang staff. 

OurTeam

NAME POSITION QUALIFICATION EMAIL
Dr. Jerome Tan Tsen Chuen
Head, Consultant Haematology
MBBS, MMed, MRCP, Fellowship in Clinical Haematology
romeje@gmail.com 
Dr. Rafizanur Ramli Deputy Head, Medical Officer BASc (Microbiology) rafizanur@moh.gov.my 
Syed Carlo Admund Research Officer MD  syedcarlo@moh.gov.my 
SN Nor Khazirah Binti Zaini Staff Nurse (Admin Manager) Diploma in Nursing khazirahzaini@yahoo.com 
SN Wirdatulain Mohd mastana Staff Nurse Diploma in Nursing wirdatulain2105@gmail.com 
Sazlinahazami Mohd salleh Administrative Assistant
Diploma sazlina.hazami8@gmail.com 

 

InvestigatorsHighlight

Image

 

Head of CRC, Consultant Clinical Haematologist, Hospital Ampang, Selangor

Email: romeje@gmail.com  

MBBS (UM), MMed (NUS), MRCP (UK), Fellowship in Clinical Haematology

Areas of interest: Malignant haematology eg. leukaemias, lymphomas, multiple myeloma and general haematology

Awards and achievements:

  • Top recruiter in the EGM for a Follicular Lymphoma trial

Dr. Jerome Tan is a full-time consultant clinical haematologist currently based in the Department of Haematology of Hospital Ampang Selangor, the national referral haematology hospital for the Ministry of Health Malaysia. He also heads the CRC Unit of Hospital Ampang Selangor. He is a certified clinical trainer and supervisor for the national clinical haematology subspecialty fellowship programme for the Ministry of Health, Malaysia. He is also an honorary member of Asia Pacific Leukaemia Consortium and has previously served as a council member of the Malaysian Society of Haematology. Dr. Jerome is a key opinion leader and frequently is invited to speak at various  haematology educational and CME programmes nationwide. He is an active  clinician and has served in several major hospitals in Sabah, Perak and Selangor. He is also active in various haematology clinical trials as a principal and sub-investigator. 

Research Highlights

Various industry sponsored Phase 3 clinical trials in Lymphomas, Chronic Myeloid Leukaemia and Acute Myeloid Leukaemia

Project Highlights

Image
NMRR-18-1266-41897
A multicentre international randomized parallel group double –blinded placebo-controlled . Clinical trial of EMPAgliflozin once daily to assess cardio-renal outcomes in patients with CKD. EMPA-KIDNEY Trial
NMRR-18-1349-39723 Aldosterone bloCkade for Health Improvement EValuation in End-stage renal disease ACHIEVE
NMRR-19-3508-51990 A multicentre , observational study of patients – Microangiopathic thrombocytopenia by the Asian-Pasific microangiopathic thrombocytopenia (APMAT) NetworkAPMAT 2.0
NMRR-22-02075-TMQ Early Oral Step-Down Antibiotic Therapy Versus Continuing Intravenous Therapy For Uncomplicated Gram-Negative Bacteraemia (the INVEST trial) INVEST
NMRR-23-02467-3JV Early intravenous to oral antibiotic switch in uncomplicated Staphylococcus aureus bacteraemia (EVOS)
NMRR-20-1856-56112 A Phase III, Randomized, Open-Label, Active-Controlled, Multicenter Study Evaluating The Efficacy And Safety Of Crovalimab Versus Eculizumab In Adult And Adolescent Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Not Previously Treated With Complement Inhibitors (BO42162)
NMRR-22-00405-WOB A Randomized, Open-Label, Ravulizumab-Controlled Study to Evaluate the Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy in Patients with Paroxysmal Nocturnal Hemoglobinuria who are Complement Inhibitor Treatment-Naive or Have Not Recently Received Complement Inhibitor Therapy ( R3918-PNH-2021)
NMRR-22-02493-GDM An Open-Label Extension Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of Pozelimab and Cemdisiran Combination Therapy in Patients with Paroxysmal Nocturnal Hemoglobinuria R3918-PNH-2050)
NMRR-20-3080-56265 An Open-Label, Single-Arm, Phase 2 Study to Evaluate the Safety, Pharmacokinetics, and Biologic Activity of Pegcetacoplan in Pediatric Patients with Paroxysmal Nocturnal Hemoglobinuria (APL2-PNH-209)
NMRR-21-1457-60074 A phase III, multi-center, open-label, randomized study of oral asciminib versus Investigator selected TKI in patients with newly diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase (CABL001J12301)
NMRR-21-1540-59591 A phase 3b, multi-center, open-label treatment optimization study of oral asciminib in patients with Chronic Myelogenous Leukemia in chronic phase (CML-CP) previously treated with 2 or more tyrosine kinase inhibitors (CABL001A2302)
NMRR-18-2297-43730 An Open Label, Non-Randomized, Multi-Center Extension Study to Evaluate the Long Term Safety and Efficacy of APL-2 in the treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH).(APL2-307)
NMRR-17-895-34856 Phase 3 open-label, multicenter, randomized study of ASP2215 versus salvage chemotherapy in patients with relapsed or refractory Acute Myeloid Leukemia (AML) with FLT3 mutation (2215-CL-0303)
NMRR-21-01964-JHU A Phase 3, Double-blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Mitapivat in Subjects With Non–Transfusion-Dependent Alpha- or Beta-Thalassemia (ENERGIZE) (AG348-C-017)
NMRR-22-01999-0L8 A multinational, open-label, randomised, controlled study to investigate efficacy and safety of NNC0365-3769 (Mim8) in adults and adolescents with haemophilia A with or without inhibitors (frontier 2)
NMRR-21-01965-4JL A Phase 3, Double-blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Mitapivat in Subjects With Transfusion-Dependent Alpha- or Beta-Thalassemia (ENERGIZE-T) (AG348-C-018)
NMRR-19-285-46613 An Open-label, Long-term Safety and Efficacy Study of Fitusiran in Patients with Hemophilia A or B, with or without Inhibitory Antibodies to Factor VIII or IX (LTE15174
NMRR-22-02426-BFW An Open-label Study to Evaluate the Long-term Safety of BCX9930 Monotherapy in Subjects with Paroxysmal Nocturnal Hemoglobinuria (BCX9930-205)
NMRR-21-1540-59591 A phase 3b, multi-center, open-label treatment optimization study of oral asciminib in patients with Chronic Myelogenous Leukemia in chronic phase (CML-CP) previously treated with 2 or more tyrosine kinase inhibitors (CABL001A2302)
NMRR-21-1457-60074 A phase III, multi-center, open-label, randomized study of oral asciminib versus Investigator selected TKI in patients with newly diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase (CABL001J12301)
NMRR-20-2678-56821 A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL) (MOR208C310)
NMRR-17-1114-36047 Cytopeutics® Umbilical Cord Mesenchymal Stem Cells (Cyto-MSC) for Patients with Grade II - IV Acute Graft-Versus-Host Disease: A Phase I/II Clinical Study (POD0030/CP/R)
NMRR-15-1121-26592 Phase 3, prospective, multi-center, open label study to investigate safety, immunogenicity and hemostatic efficacy of PEGylated factor VIII (BAX 855) in previously untreated patients (PUPs) and minimally treated patients (MTPs) < 6 years with severe hemophilia A (FVIII < 1%) (BAX261203)
NMRR-19-285-46613 An Open-label, Long-term Safety and Efficacy Study of Fitusiran in Patients with Hemophilia A or B, with or without Inhibitory Antibodies to Factor VIII or IX (LTE15174)
NMRR-19-1963-48953 Efficacy and Safety of Concizumab prophylaxis in patients with haemophilia A or B with
 inhibitors (explorer7)
NMRR-19-1915-48954 Efficacy and Safety of Concizumab prophylaxis in patients with haemophilia A or B without inhibitors (explorer8)
NMRR-22-01999-0L8 A multinational, open-label, randomised, controlled study to investigate efficacy and safety of NNC0365-3769 (Mim8) in adults and adolescents with haemophilia A with or without inhibitors (frontier 2)
NMRR-23-02387-VRH Open-label, long-term safety and efficacy study of Mim8 in participants with haemophilia A with or without inhibitors (frontier 4)

List of Publications associated with CRC HAMP

Services at CRC Hospital Ampang

CRC Hospital Ampang provides training through workshops and consultations:

  • Promote research activities :
    • Conduct courses such as Introduction to Clinical Research, Basic Biostatistics Workshop and Good Clinical Practice (GCP).
    • Conduct regular in - house Continuous Professional Development (CPD).
    • Run research clinics – provide consultation on research methodology, study design, protocol and statistical analysis.
  • Support and facilitate research activities in the hospital through the provision of : 
    • Database of clinicians interested in research – by interest areas, track record on Industry Sponsored Research (ISR).
    • Technical support such as statistical analysis.
    • Administrative support such as providing research assistants and study coordinators.
    • Facility support such as statistical software, study equipment for ISR and Investigator Initiated Research (IIR) such as fridges, centrifuge machines, etc.
  • Assist in the process of registration for National Medical Research Register (NMRR) and application of grants for research.
  • Participate in clinical trials and other research initiated or coordinated by the ICR.
  • Establish collaboration with local, regional and international research organizations in the pursuit for excellence in clinical research in the country.

Fireproof File Cabinets

Pharmaceutical Refrigerators

Store Room

Freezer -20°C

Processing Room

Freezer -80°C

Refrigerated Centrifuge

Daycare

Meet Our Collaborators

CRC Hospital Ampang, Selangor

Clinical Research Centre
Hospital Ampang,
Level 3, 
Specialist Office,
Hospital Ampang,
Jalan Mewah Utara,
Pandan Indah,
68000 Ampang, Selangor Darul Ehsan

 

Main Phone: +603-42896000 Ext: 6559

Email: ampangcrc@gmail.com 

 

ICR
National Institutes of Health (NIH)
Ministry of Health Malaysia
Institute For Clinical Research
Block B4, National Institutes of Health (NIH)
No.1, Jalan Setia Murni U13/52, Seksyen U13
40170 Shah Alam, Selangor Darul Ehsan
Malaysia
 
Phone: 603-3362 7700
Email: contact@crc.gov.my
 

NIH Official Portal

Client 1

Follow us on